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Abstract
Background: Hepatocellular carcinoma (HCC) is the leading cause of cancer-related deaths worldwide. The only
drug currently approved for clinical use in the treatment of advanced HCC is sorafenib. However, many patients
with HCC show reduced sensitivity to sorafenib during treatment. SIRT3, a member of the mammalian sirtuin family,
is a tumor suppressor in certain tumor types. However, only few studies have investigated the effects of SIRT3 on
tumor prognosis and sorafenib sensitivity in patients with HCC. Here, we aimed to investigate the correlation
between SIRT3 expression and glucose metabolism and proliferation in HCC and discover effective compounds that
increase endogenous SIRT3 modulation effect of sorafenib.
Methods: To determine the correlation between SIRT3 and glucose related proteins, immunostaining was
performed with liver cancer tissue using various antibodies. To investigate whether the expression of SIRT3 in HCC
is related to the resistance to sorafenib, we treated sorafenib after the modulation of SIRT3 levels in HCC cell lines
(overexpression in Huh7, knockdown in HepG2). We also employed PD0332991 to modulate the SIRT3 expression in
HCC cell and conducted functional assays.
Results: SIRT3 expression was downregulated in high glycolytic and proliferative HCC cells of human patients,
xenograft model and HCC cell lines. Moreover, SIRT3 expression was downregulated after sorafenib treatment,
resulting in reduced drug sensitivity in HCC cell lines. To enhance the anti-tumor effect of sorafenib, we employed
PD0332991 (CDK4/6-Rb inhibitor) based on the correlation between SIRT3 and phosphorylated retinoblastoma
protein in HCC. Notably, combined treatment with sorafenib and PD0332991 showed an enhancement of the anti-
tumor effect in HCC cells.
Conclusions: Our data suggest that the modulation of SIRT3 by CDK4/6 inhibition might be useful for HCC therapy
together with sorafenib, which, unfortunately, has limited efficacy and whose use is often associated with drug
resistance.
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Background
Hepatocellular carcinoma (HCC) is a leading cause of
cancer-related deaths worldwide [1]. Patients with early-
stage HCC are asymptomatic; hence, HCC is usually de-
tected at intermediate or advanced stages, in which pa-
tients cannot receive curative treatments such as
ablation, surgical resection, or liver transplantation [2].
Although surgical treatment has improved the disease
outcome, the risk of recurrence remains substantial even
for early HCC. In patients with advanced HCC, sorafenib
(Nexavar), an orally active multikinase inhibitor, has
been used as a first-line chemotherapeutic agent [3].
Despite extending the median survival by 3–5months,
the high resistance rate and serious adverse side effects
have significantly limited the benefits of sorafenib ther-
apy [4–6]. Therefore, there is an increasing need for a
strategy to enhance the effects of sorafenib anti-cancer
activity.
Sirtuins (SIRT1–7) have emerged as important regula-
tors of tumorigenic processes such as proliferation, cell
cycle progression, cell survival, metabolism, and angiogen-
esis [7–9]. SIRT3, the best characterized mitochondrial
sirtuin, deacetylates and activates several enzymes in-
volved in cellular redox balance and defense against oxida-
tive damage [10–12]. Several reports suggest that SIRT3
has a dual role in cancer [13–15]. SIRT3 functions as an
oncogene in oral cancer and melanoma by maintaining
ROS levels under a certain threshold to prevent apoptosis
and promote cell proliferation [16, 17]. In contrast, SIRT3
has been identified as a tumor suppressor in HCC [18,
19], breast cancer [20], ovarian cancer [21], and leukemia
[22]. Further, it has been reported that SIRT3 plays a role
in metabolic reprogramming (Warburg) and in triggering
cell death under stress conditions [23, 24]. Indeed, high
SIRT3 expression is correlated with favorable outcomes
and an increase in the overall survival rate of patients with
HCC [25]. In this regard, regulation of SIRT3 expression
might be a novel strategy to investigate more personalized
therapies against cancers. In addition, SIRT3 expression
levels affect sensitivity to chemotherapeutic agents in
HCC [26].
In this study, we aimed to investigate the correlation
between SIRT3 expression and glucose metabolism and
proliferation in HCC. In addition, because a few com-
pounds have been explored to modulate SIRT3 activity
[27, 28], we also attempted to identify effective com-
pounds that increase the endogenous SIRT3 modulation
mediated by the anti-cancer effect of sorafenib.
Methods
Human HCC samples
This study was approved by the Institutional Review
Board at Yonsei University Health System Severance
Hospital (Seoul, South Korea), and the study was
conducted using the current guidelines for ethical re-
search (Yonsei IRB number: 4–2015-0904). The selec-
tion of patients was performed as described previously
[29].
Chemicals
PD0332991 was purchased from TOCRIS Bioscience
(Bristol, UK) and sorafenib was purchased from Santa
Cruz (Dallas, TX, USA). PD0332991 and sorafenib were
dissolved in DMSO (Sigma Aldrich, St. Louis, MO,
USA) at a concentration of 10 mM. All reagents were
stored at − 80 °C.
Cell lines and cell culture
The human HCC cell lines HepG2, Hep3B, skHep1, and
Huh7 were purchased from the Korean Cell Line Bank.
HepG2 was cultured in RPMI, and Hep3B, skHep1, and
Huh7 were cultured in Dulbecco’s modified Eagle’s
medium (DMEM). All media were supplemented with
10% fetal bovine serum (FBS; Hyclone) and 1% penicillin
streptomycin. Cells were maintained in a humidified in-
cubator with 5% CO2 at 37 °C. For the formation of
three-dimensional spheroids, Costar® Ultra-Low attach-
ment multiple-well plates (MerkKGaA → Corning,
Darmstadt, Germany) were used. HCC cells were plated
at 5000 cells/well and centrifuged at 179×g for 1 min.
Spheroids were observed 1–2 days after plating. Hep3B,
skHep1, and Huh7 cell lines were plated and incubated
for 24 h before transfection. Lipofectamine or RNAi-
MAX reagent (Invitrogen, Carlsbad, CA, USA) was used
to perform siRNA transfection following the manufac-
turer’s instructions. The plasmids for hSIRT3 (sc-61,
555-SH) or scramble shRNA (sc-108,060) were cotrans-
fected into HepG2 cells using Lipofectamine 2000 (Invi-
trogen, 12,566,014). After 72 h of incubation, the cells
were treated with puromycin (2 μg/mL) to generate
stable cell line clones.
Cell proliferation assay and glucose measurement
WST-1 colorimetric assays (Roche, Mannheim,
Germany) for cell viability were performed 48 h after
treatment according to the manufacturer’s recommenda-
tions. Huh7 cells were placed in 96-well plates and being
transfected with MOCK or pcDNA-SIRT3 plasmid.
After 48 h of treatment, the glucose uptake was deter-
mined using Glucose Assay (Promega, Germany) accord-
ing to the manufacturer’s recommendation. Absorbances
at 440 nm and 640 nm were measured using a micro-
plate reader (Molecular Devices, CA, USA).
RNA isolation and sequencing
Total RNA was isolated using TRIzol reagent (Invitro-
gen). RNA quality was assessed by Agilent 2100 bioana-
lyzer using the RNA 6000 Nano Chip (Agilent
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Technologies, Amstelveen, The Netherlands), and RNA
quantification was performed using ND-2000 Spectropho-
tometer (Thermo Inc., DE, USA). For control and test
RNA samples, library was constructed using QuantSeq 3′
mRNA-Seq Library Prep Kit (Lexogen, Inc., Austria) ac-
cording to the manufacturer’s instructions. Briefly, 500 ng
total RNA was prepared for each sample, an oligo-dT pri-
mer containing an Illumina-compatible sequence at its 5′
end was hybridized to the RNA, and reverse transcription
was performed. After degradation of the RNA template,
second strand synthesis was initiated by a random primer
containing an Illumina-compatible linker sequence at its
5′ end. The double-stranded library was purified using
magnetic beads to remove all reaction components. The
library was amplified to add the complete adapter se-
quences required for cluster generation. The amplified li-
brary was purified, and high-throughput sequencing was
performed as single-end 75 sequencing using NextSeq 500
(Illumina, Inc., USA).
Real-time PCR
Total RNA was extracted with TRIzol (Invitrogen) and
cDNA was synthesized from 500 ng of total RNA using
the ReverTra Ace qPCR RT Master Mix with gDNA Re-
mover (Toyobo, Osaka, Japan). Quantitative RT-PCR
was conducted on C1000 a→ a C1000 Thermal Cycler
(Bio-Rad) using SYBR Green Real-time PCR Master Mix
(Toyobo, Osaka, Japan). Gene expression levels were
normalized with beta-2 microglobulin (B2M) mRNA ex-
pression levels of corresponding cDNA samples. All PCR
primers were purchased from Bioneer (Daejeon, Korea).
The following primers were used: SIRT3 (Forward 5′-
GAAACTACAAGCCCAACGTCA-3′, Reverse 5′-
AAGGTTCCATGAGCTTCAACC-3′), RB1 (Forward 5′-
GAAGCAACCCTCCTAAACCAC-3′, Reverse 5′-




Western blotting was performed as described previously
[29]. The primary antibodies in the present study were:
SIRT3 (Cell Signaling Technology, Danvers MA, USA;
clone C73E3; dilution 1:1000), CDK4 (DCS156, 1:1000),
CDK6 (DCS83, 1:1000), Phospho-Rb (Ser807/811)
(D20B12, 1:1000), Rb (4H1, 1:2000), PCNA (D3H8P, 1:
2000), GLUT1 (1:2000) from Abcam (Cambridge, UK),
and Ki67 (Santa Cruz, Dallas TX, USA; MIB-1, 1:500).
Western blotting experiments from biological replicates
showed similar expression data, attesting to the reprodu-
cibility of the results. We used ChemiDoc XRS (Biorad),
which enables direct digital visualization of chemilumin-
escent western blots for the image of signals accumu-
lated in the chemiluminescence reaction. For band
quantification, images were analyzed using Image Lab
software (Bio-Rad, Hercules, California, USA).
Flow cytometry analysis
For quantification of apoptosis, double staining was per-
formed according to the manufacturer’s instructions
using Annexin V-FITC Apoptosis Detection Kit (BD
Pharmingen™, NJ, USA) and propidium iodide (PI). After
HepG2 and Huh7 cells were collected after incubation
with indicated compound, cells were washed twice with
ice-cold PBS and resuspended in 200 μL of binding buf-
fer. Annexin V-FITC was added to the cells and incu-
bated for 15 min in the dark at 25 °C. PI (10 mL) was
added to the tube followed by 5 min of incubation at
4 °C in the dark. After incubation, the samples were ana-
lyzed by a flow cytometer using CELL Quest software
(BD) and 1.0 × 105 events per sample were counted. The
fraction of cell population in different quadrants was an-
alyzed using quadrant statistics. Cells in the lower right
quadrant (Annexin-V+/PI−) represented early apoptosis
and those in the upper right quadrant (Annexin-V+/PI+)
represented late apoptosis. For cell cycle analysis, after
HepG2 and Huh7 cells were collected after incubation
with indicated compound, the cells were incubated in
70% ethanol at 4 °C for 1 h. After washing with PBS, cells
were incubated with PI at a concentration of 5 μg/mL
and RNaseA at a concentration of 10 mg/mL for 30
min–4 h at 37 °C. The DNA contents were analyzed
using FlowJo Software (Tree StarInc., Ashland, OR,
USA).
Migration assay
Chemomigration assays were performed using 24-well
plates with uncoated polycarbonate membrane inserts
(BioCoat; BD Biosciences, Heidelberg, Germany). A total
of 50,000 cells in medium containing 0.1% FBS and so-
rafenib, PD0332991, or combination of sorafenib and
PD033291 were added onto the insert. The lower well
was filled with a medium supplemented with 10% FBS.
Twenty-four hours later, the cells that had migrated
were fixed in 100% methanol and stained with 1.5% (w/
v) toluidine blue in water. Images were recorded using
an Olympus BX53 microscope with Olympus Cell Sens
software (Carl Zeiss Microscopy, GmbH, Jena,
Germany).
Immunostaining
Immunohistochemistry (IHC) and immunofluorescence
(IF) were performed as described previously [30]. After
antigen retrieval, immunostaining was performed using
various antibodies. The primary antibodies used were:
SIRT3 (Cell Signaling Technology, Danvers MA, USA;
clone C73E3; dilution 1:500); Ki67 (Dako, Glostrup,
Denmark; MIB-1; 1:500); GLUT1 (1:500), and Ki67 (SP6,
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1:500) from Abcam (Cambridge, UK). Images were re-
corded using an Olympus BX53 microscope with Olym-
pus Cell Sens software (Carl Zeiss Microscopy, GmbH,
Jena, Germany). The percentage of Ki67-positive cells
and phosphorylated retinoblastoma protein (pRb) was
calculated by counting the number of cells with DAPI-
stained nuclei.
The Cancer genome atlas (TCGA) data analysis
mRNA levels of TCGA liver HCC data were obtained
from the OncoLnc TCGA data portal (www.oncolnc.
org). A set of 360 HCC samples with high and low gene
expression groups (50–50 percentile) was used for cor-
relation graphs of two different genes. GraphPad Prism
5 (GraphPad Software, San Diego, CA, USA) was used
for mapping.
Statistical analysis
Statistical analyses were performed using GraphPad
Prism Software (GraphPad Software, Inc., San Diego,
CA). Results are expressed as mean ± SE (range). P
values < 0.05 were considered statistically significant.
Comparisons between groups were made using the
Mann-Whitney test.
Results
Expression of SIRT3 in patients with HCC
Imaging with 18F-fluorodeoxyglucose (FDG) positron
emission tomography/computed tomography (PET/CT)
was used to evaluate glucose metabolism. To investigate
the correlation between glucose uptake and SIRT3 ex-
pression, 21 patients with HCC were divided into two
groups according to 18F-FDG uptake: 9 patients with
high glycolytic HCC with high 18F-FDG uptake and 12
with low glycolytic HCC with low 18F-FDG uptake. The
mRNA expression of SIRT3 was higher in the low glyco-
lytic group than in the high glycolytic group (Fig. 1a). To
confirm our observation, we performed IHC analysis
with HCC tissues from the two groups (n = 6 in each
group). In patients with low FDG uptake, low membran-
ous GLUT1 expression, low Ki67 expression, and high
SIRT3 expression were observed in the tumor region
(Fig. 1b and supplementary data 1). High Ki67 and low
SIRT3 expression levels were observed in patients with
high GLUT1 expression in the high FDG uptake group.
In addition, we also confirmed the expression of SIRT3
in patients with HCC by western blotting (supplemen-
tary data 2). Downregulation of SIRT3 was determined
also in HCC patients with high 18F-FDG uptake com-
pare with low 18F-FDG uptake. Altogether, SIRT3 ex-
pression seemed to be associated with glycolytic
metabolism and cell proliferation in patients with HCC.
Differential expression of SIRT3 in HCC cells
The expression of SIRT3 was assessed in three HCC cell
lines (HepG2, Hep3B and Huh7), liver adenocarcinoma
cell line with characteristics of liver sinusoidal endothe-
lial cells (SK-Hep1) [31], and their xenograft models
with different rates of proliferation and glycolysis.
HepG2 cells showed the highest expression of SIRT3 at
the mRNA and protein levels (Fig. 2a, b and supporting
data),.. Similar to human patients with HCC, an inverse
correlation between GLUT1 and SIRT3 was observed in
an HCC xenograft model (Fig. 2c). Moreover, there was
a significant negative correlation between SIRT3 and
Ki67. HepG2 and Hep3B cells had low Ki67 and high
SIRT3 expression, whereas Huh7 and SK-HEP1 cells
had high Ki67 and low SIRT3 expression. These results
were consistent with the TCGA database analysis of hu-
man HCC samples (Supporting data 3A and 1B). Spear-
man’s correlation also showed a significant negative
correlation between SIRT3 and Ki67 (Spearman’s coeffi-
cient r = − 0.3093, P < 0.0001), and SIRT3 and HK2
(Spearman r = − 0.239, P < 0.0001). To further corrobor-
ate our findings, SIRT3 was overexpressed in Huh 7 cells
with low basal SIRT3 expression. Overexpression of
SIRT3 reduced the expression of Ki67 and GLUT1 and
also significantly reduced glucose uptake (Fig. 2d and e).
Taken together, our results indicate that SIRT3 expres-
sion is negatively correlated with glycolytic metabolism
and proliferation in HCC cells and in their xenograft
models.
The relationship between SIRT3 expression levels and
sorafenib treatment
Because our results suggested a crucial role of SIRT3 in
HCC, we next investigated whether the expression of
SIRT3 was changed by sorafenib treatment by incubat-
ing HCC cell lines with sorafenib for 48 h. We observed
that the expression of SIRT3 in HCC cells decreased
after treatment with 10 μM sorafenib (Fig. 3a). Further-
more, a more prominent decrease in Huh7 cell prolifera-
tion was observed in cells transfected with SIRT3 than
in cells transfected with MOCK (Fig. 3b and c). In
addition, we generated SIRT3 KD stable cell line using
HepG2 cells. The sensitivity against sorafenib was sig-
nificantly reduced in SIRT3 KD stable cells compare
with control stable cells, suggesting that the expression
of SIRT3 enhances the sensitivity of HCC cells to so-
rafenib (Fig. 3d and supplementary data 4). Together,
these results suggest that modulation of SIRT3 might
be an effective strategy to increase the sensitivity to
sorafenib.
Negative correlation between SIRT3 and pRb
PD0332991, a highly selective inhibitor of CDK4/CDK6
kinases with the ability to block phosphorylation activity
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of Rb, has become a novel therapeutic candidate for
HCC [32]. We assessed the expression of pRb in pa-
tients with HCC to determine whether PD0332991
can be a candidate drug to increase the sensitivity of
sorafenib by modulation of SIRT3 expression. IHC
was performed using antibody specific for pRb using
HCC xenograft models. Huh7 and skHep1-xenograft
models with low SIRT3 expression showed high ex-
pression of pRb. Thus, the expression of pRb and
SIRT3 had a negative correlation in HCC xenograft
models (Fig. 4a and supplementary data 5A). In hu-
man HCC, Rb mRNA levels were significantly higher
and those of SIRT3 mRNA were relatively lower in
the high 18F-FDG group than in the low 18F-FDG
group (Fig. 4b). Spearman’s correlation also showed a
significant negative correlation between SIRT3 and
Rb1 (Spearman’s coefficient r = − 0.3408, P < 0.0001)
expression levels in human HCC patients by TCGA
data analysis (Supplementary data 3D). Moreover, we
also observed a negative correlation between the ex-
pression of pRb and SIRT3 in human patients with
HCC (Fig. 4c and Supplementary data 5B).
SIRT3 expression is upregulated upon treatment with a
CDK4/6 inhibitor
Because a connection between SIRT3 and pRb was
identified in this study, we investigated whether
PD0332991 can modulate the expression of SIRT3 to
Fig. 1 SIRT3 expression in patients with hepatocellular carcinoma (HCC) and with different 18F-FDG uptake. a. RNA was extracted from frozen
HCC samples obtained after transsphenoidal surgery. RT-PCR was performed using probe sets specific for SIRT3. The expression of the target
genes was normalized to that of B2M (housekeeping gene) using the 2−ΔΔCt method. The boundary of the box closest to zero indicates the 25th
percentile, the line within the box marks the median, and the boundary of the box farthest from zero indicates the 75th percentile. b. Formalin-
fixed, paraffin-embedded human HCC samples were used and immunofluorescence was performed using the indicated antibodies and
counterstained with DAPI. Scale bars: 50 μm. Statistical analyses were performed using GraphPad Prism. Results are expressed as mean ± SD.
Comparisons between groups were made using the Mann-Whitney test. *P < 0.05
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enhance the sorafenib sensitivity in HCC cells. Upon
PD0332991 treatment, the expression of SIRT3 in-
creased in HepG2. In SK-HEP1 and Huh7 cells,
SIRT3 expression increased marginally compared with
that in the control (Fig. 5a). However, no significant
change was observed in Hep3B cells. It is possible
that Hep3B cells present mutations of Rb that under-
lie the relative resistance to CDK4/6 inhibition [33,
34]. Therefore, Hep3B cells were excluded from fur-
ther experiments. In addition to PD0332991 treat-
ment, we investigated the expression of SIRT3 upon
knockdown of CDK4/6 in HCC cells. Similar to that
after PD0332991 treatment, SIRT3 expression was up-
regulated in CDK4/6 knockdown HepG2 cells, Huh7
cells and SK-Hep1 cells (Fig. 5b-d). The expression of
PCNA, a proliferation marker, decreased upon CDK4/
Fig. 2 Expression of SIRT3 in hepatocellular carcinoma (HCC) cell lines and HCC xenograft models. a SIRT3 expression in four different HCC cell
lines was measured using quantitative RT-PCR. The expression level of target genes was normalized to that of the housekeeping gene B2M using
the 2−ΔΔCt method. Data are shown as the mean of three independent experiments ± SD. b Western blotting in different HCC cell lines using
antibodies against SIRT3 and actin. The images shown here are cropped and the full-length blots/gels are presented in Additional file 2: Fig. S1. c
Formalin-fixed, paraffin-embedded liver tissues from HCC xenograft model were used. Immunohistochemistry was performed using antibodies
against SIRT3, GLUT1, and Ki67 and counterstained with hematoxylin. Scale bars: 20 μm. d Huh7 cells were transfected with MOCK vector and
pcDNA-SIRT3. After 48 h of incubation, protein was extracted and the expression of SIRT3, Ki67, and actin was determined using western blotting.
The images shown here are cropped and the full-length blots/gels are presented in Additional file 2: Fig. S2. e Glucose uptake was measured
using Glucose-Glo Assay. Data are shown as the mean of three independent experiments ± SD. Statistical analyses were performed using
GraphPad PrismComparisons between groups were made using the Mann-Whitney test. *P < 0.01
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Fig. 3 The relationship between SIRT3 expression levels and sorafenib treatment. a Reduced SIRT3 expression upon sorafenib treatment in
hepatocellular carcinoma (HCC) cells. HCC cells were incubated with DMSO, 1 μM sorafenib, or 10 μM sorafenib. After 48 h, the level of SIRT3 and
actin was measured by western blotting. The images shown here are cropped and the full-length blots/gels are in Additional file 2: Fig. S3. b
Huh7 cells were transfected with MOCK or pcDNA-SIRT3. After 24 h, the cells were treated with 10 μM sorafenib for further 24 h and then western
blotting was carried out to determine SIRT3 and β-actin expression. The images shown here are cropped and the full-length blots/gels are in
Additional file 2: Fig. S4. c Cell proliferation was measured using WST-1 assays. Data are shown as the mean of three independent experiments ±
SD. d SIRT3 KD or control stable cell line were incubated with indicated concentration of sorafenib. After 48 h, cell proliferation was measured
using WST-1 assays. Statistical analyses were performed using GraphPad Prism. Results are expressed as mean ± SD. Comparisons between groups
were made using the Mann-Whitney test. *P < 0.05; **P < 0.01
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6 silencing, which had an effect similar to that of
treatment with PD0332991 (Fig. 5b-d).
Our data suggested that SIRT3 expression is nega-
tively correlated with glucose metabolism (Fig. 1a and
b). Thus, we assessed the expression of glycolysis- and
TCA-related genes after CDK4/6 inhibition in HepG2
cells by microarray analysis. A reduction in the expres-
sion of glycolysis-related genes, including SLC2A1 (fold
change: 0.12), PFKP (fold change: 0.341), PKM (fold
change: 0.457), and HK2 (fold change: 0.693) was ob-
served in CDK4/6 KD HepG2 cells (Fig. 5e). In
addition, the most dysregulated genes in the two sam-
ple groups (scramble vs. CDK4/6 KD) were associated
with the following categories: DNA replication, meiotic
cell cycle process, chromosome segregation, regulation
of fatty acid oxidation, lipid catabolic process, and regu-
lation of lipid catabolic process (Supporting data 3).
The rate of dysregulation in glycolysis-related genes
after PD0332991 treatment was smaller compared with
that after CDK4/6 KD (Fig. 5e). Thus, we identified a
novel mechanism to modulate SIRT3 expression by
CDK4/6 inhibition, resulting in the inhibition of gly-
colysis and cell proliferation.
Enhancement of anti-cancer effect of sorafenib during
combination treatment with PD0332991
We next aimed to investigate whether upregulation of
SIRT3 by the CDK4/6 inhibitor PD0332991 could en-
hance the anti-cancer effect of sorafenib on HCC cells.
We performed combination treatment with sorafenib
and PD0332991 in HepG2. Both SIRT3 mRNA and pro-
tein expression were upregulated in HepG2 cells ex-
posed to the two drugs (Fig. 6a and b). In these
conditions, we also noticed a more pronounced reduc-
tion of cell viability compared with single treatment
(Fig. 6c). To confirm, we generated 3-dimensional spher-
oids from HepG2 cells. The spheroid size of the HepG2
cells after the combined treatment was more reduced,
Fig. 4 Negative correlation between SIRT3 and retinoblastoma protein (Rb). a Formalin-fixed, paraffin-embedded (FFPE) liver tissues from HCC
xenograft model were used. Immunohistochemistry was performed using antidies against phosphor-Rb (pRb) and counterstained with
hematoxylin. Scale bars: 50 μm. b RNA was extracted from frozen HCC samples obtained after transsphenoidal surgery. RT-PCR was performed
using probe sets specific for Rb. The expression of the target genes was normalized to that of B2M (housekeeping gene) using the 2−ΔΔCt
method. The boundary of the box closest to zero indicates the 25th percentile, the line within the box marks the median, and the boundary of
the box farthest from zero indicates the 75th percentile. *P < 0.05. c FFPE liver tissues from human patients with HCC were used.
Immunohistochemistry was performed using antibodies against SIRT3 (left) and pRb (right) and counterstained with hematoxylin. Scale
bars: 50 μm
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Fig. 5 (See legend on next page.)
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compared with that after single treatment. We also per-
formed western blotting and observed increased level of
SIRT3 after PD0332991 treatment, and after the com-
bined treatment, compared with that after control and
sorafenib treatment (Sup data 7). Huh7 cells showed the
same results as HepG2 with the exception of SIRT3
mRNA expression because of the very low basal level of
SIRT3 mRNA in Huh7 cells (Fig. 6d and e). To confirm
the increased anti-cancer effect of the combined treat-
ment, we also measured migration of cells after treat-
ment with soranfenib, PD0332991 or their combination.
The migration of HepG2 and Huh7 cells were further
reduced after the combined treatment compared with
that after single treatment (Fig. 7a, b and c). In parallel,
we performed cell cycle analysis, immunostaining of
ki67 and apoptosis assay in HepG2 cells and Huh7 cells.
In cell cycle analysis, we observed reduced reduction of
G2/M phase compare with single treatment in HepG2
cells. In Huh7, G2/M and S phase were reduced after
combined treatment with both compound (Supplementary
data 8A). Also, immunostaining of Ki67 was determined in
HepG2 and huh7 cells after combined treatment. Ki67
positive cells were dramatically decreased in cells with com-
bined treatment (Supplementary data 8B and C). Moreover,
annexin V-PI staining demonstrated that combined treat-
ment with sorafenib and PD033291 increased early and late
apoptosis (Fig. 7d and supplementary data 8D). Altogether,
these results show that upregulation of SIRT3 by CDK4/6
inhibition enhances the sensitivity to sorafenib treatment in
HCC cells.
Discussion
Several studies have emphasized the importance of
SIRT3 in carcinogenesis [9, 24, 35]. However, there have
been few studies on the mechanisms that control SIRT3
expression or on the discovery of clinically applicable
drugs that can modulate it. In this study, we investigated
a novel function of CDK4 /6 inhibitor as an inducer of
SIRT3, resulting in enhanced sensitivity to sorafenib
treatment in HCC cells.
To date, SIRT3 is known as a tumor suppressor gene
[23], and overexpression of SIRT3 reduces cell growth
and proliferation in HCC [23, 25, 26]. SIRT3 also in-
duces apoptosis in abnormal cells through the upregula-
tion of MnSOD, p53, Bax, and Fas [19]. Wang et al.,
determined patient survival and outcome in patients
with HCC according to SIRT3 expression [36]. In fact,
reduced expression of SIRT3 was associated with poor
prognosis, whereas intra-tumoral SIRT3 expression was
reported as a good prognostic factor in the early stages.
So far, the effect of SIRT3 on glucose metabolism has
been studied in cancers other than HCC [37–39]. Finley
et al. proposed that SIRT3 loss increases ROS levels and
promotes tumorigenesis by altering global cellular me-
tabolism [24]. In this study, patients with HCC were di-
vided into low and high glycolytic groups by 18F-FDG-
PET analysis. Consistent with previous results with other
tumor types, we found high SIRT3 and low Ki67 expres-
sion in the low glycolytic group of patients with HCC.
Thus, our study suggests that SIRT3 expression is asso-
ciated with glycolysis and proliferation in human HCCs.
Indeed, upregulation of SIRT3 by CDK4/6 inhibition
and treatment with PD0332991 induced the downregula-
tion of glycolysis-related genes in our gene analysis.
Selective CDK4/6 inhibitors, including PD0332991,
are currently used for the treatment of a variety of
tumor types, including breast cancer, melanoma, and
non-small cell lung cancer [40–42]. In this study, we
found that CDK4/6 inhibition by treatment with
siCDK4/6 or PD0332991 upregulated SIRT3 expres-
sion. Previous studies have determined that SIRT1 is
involved in the regulation of SIRT3 expression by
deacetylation and binding as a transcription factor
[43]. In addition, SIRT1 is involved in the deacetyla-
tion of retinoblastoma (Rb), leading to dissociation of
E2F1 and enhanced cell proliferation [44]. Therefore,
there might be a correlation among SIRT3, SIRT1,
and pRB expression levels in HCC cells. Indeed, there
was a negative correlation between SIRT1 and SIRT3
expression in data from patients with HCC from the
TCGA database (Supplementary Fig. 1C). However,
the mechanism of SIRT3 expression by CDK4/6
inhibition remains unclear, and should be investigated
in future studies.
Sorafenib has not been effective in patients with ad-
vanced HCC, and its use is often associated with reduc-
tion of drug sensitivity. Therefore, it is very important to
identify a drug candidate that can replace or be used to-
gether with sorafenib. Tao et al. found that upregulation
of SIRT3 expression can enhance the sensitivity of HCC
(See figure on previous page.)
Fig. 5 SIRT3 induction after PD0332991 treatment. a HepG2, Hep3B, SK-Hep1, and Huh7 cells were incubated with DMSO, 1 μM PD0332991, or
10 μM PD0332991. After 48 h, SIRT3 and actin levels were evaluated using western blotting. The images shown here are cropped and the full-
length blots/gels are presented in Additional file 2: Fig. S5. b-d HepG2 cells (b), Huh7 cells (c), SK-Hep1 cells (d) were transfected with scrambled
siRNA oligos or siRNA oligos against CDK4/6. After 48 h, western blotting was performed to detect indicated proteins. The images shown here are
cropped and the full-length original blots are shown in Additional file 2: Fig. S6, S7 and S8. e Fold change of the indicated genes obtained by
gene expression profiling of HepG2 cells after transfection with scrambled siRNA oligos or siRNA oligos targeting CDK4/6. All data are uploaded
into the GEO database under the accession number GSE145389
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Fig. 6 Increased sensitivity to sorafenib after combined treatment with sorafenib and PD0332991. a HepG2 cells were incubated with DMSO or
10 μM PD0332991 with or without 1 μM sorafenib. After 48 h, SIRT3 levels were analyzed using qRT-PCR. The expression level of target genes was
normalized to that of the housekeeping gene B2M using the 2−ΔΔCt method. Data are shown as the mean of three independent experiments ±
SD. b Cells were treated as in (A). Protein was extracted and the expression of SIRT3 and actin was determined using western blotting. The
images shown here are cropped and the full-length blots/gels are presented in Additional file 2: Fig. S9. c In parallel, proliferation was assessed
48 h later using WST-1 assays. d Huh7 cells were incubated with DMSO, or 10 μM PD0332991 with or without 1 μM sorafenib. After 48 h, protein
was extracted and the expression of SIRT3 and actin was determined using western blotting. The images shown here are cropped and the full-
length blots/gels are presented in Additional file 2: Fig. S10. e In parallel, proliferation was assessed 48 h later using WST-1 assays. Data from six
technical replicates were analyzed and expressed as the mean ± SD
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cells to chemotherapeutic agents [26]. In our study, we
found that the upregulation of SIRT3 by transfection in
HCC cells reduced cell proliferation and significantly in-
creased sensitivity to sorafenib. Moreover, the restor-
ation of SIRT3 by PD0332991 could increase sensitivity
to sorafenib, resulting in enhanced inhibition of prolifer-
ation and migration in HCC cells.
Thus, we propose SIRT3 expression as a predictor of
sorafenib response. To concrete our observations in the
in vitro system, preclinical studies will be conducted in
the future.18F-FDG is a surrogate imaging modality to
measure glucose metabolism in patients with HCC.
However, there are few studies on 18F-FDG imaging in
patients treated with sorafenib [45]. Our results prove
the negative correlation between the expression of
SIRT3 and glucose metabolism using human HCC tis-
sues and HCC cells in vitro. Since the expression of
SIRT3 is a predictor of response to sorafenib, [18F]
Fig. 7 The enhancement of the growth inhibition after combined treatment of sorafenib and PD0332991 in HepG2 cells and Huh7 cells. a
Migration assay was performed. Penetrating HepG2 cells and Huh7 cells after treatment with indicated compound for 24 h were fixed and
visualized by the staining of crystal violet. b, c Quantitative analyses were performed for the cells migrating through the matrigel-coated filter.
Five random fields of each test at × 200 magnifications were counted. d, f Analysis of apoptosis by Annexin V-APC/propidium iodide (PI) double
staining of HepG2 and Huh7 cells after 24 h treatment with indicated compound. Two-color flow cytometry dot plots show the percentages of
living cells as negative for both annexin V and PI; early-stage apoptotic cells as the populations testing Annexin V positive and PI negative, and
late-stage apoptotic/necrotic cells as double-positive cells. Results are represented in as mean ± SD, n = 3. Statistical analyses were performed
using GraphPad Prism. Results are expressed as mean ± SE (range). Comparisons between groups were made using the Mann-Whitney test.*, P <
0.05;**, P < 0.01;;***, P < 0.001
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FDG-PET imaging could monitor the drug sensitivity in
HCC patients clinically during sorafenib treatment.
Conclusion
In summmary, our data indicate the importance of
CDK4/6 inhibitors as a new approach to improve HCC
therapy. Moreover, our study shows that induction of
SIRT3 by CDK4/6 inhibition causes inhibition of cell
growth and glucose metabolism and increased suscepti-
bility to chemotherapy. Thus, the modulation of SIRT3
might be a novel treatment in patients with HCC and,
possibly, other cancers in which SIRT3 acts as a tumor
suppressor.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12885-020-06822-4.
Additional file 1 Supplementary Data 1. Quantification of
immunostaining. (A, C) Mean fluorescent intensity (MFI) indicating the
expression of (A) SIRT3 and membranous (C) GLUT1 from 12 patients
with high FDG uptake (n = 6) and low FDG uptake (n = 6). Quantification
of fluorescence in microscopic images stained with GFP (Green) and
DsRed (Red) was carried out using IMT i-Solution software (Martin Micro-
scope Company, Easley, USA). (B) Ki67 positive cells in positive and nega-
tive tumor regions of indicated proteins in HCC with high FDG uptake.
Statistical analyses were performed using GraphPad Prism. Results are
expressed as mean ± SD. Comparisons between groups were made using
the Mann-Whitney test. *P < 0.05; **P < 0.01. Supplementary Data 2.
SIRT3 expression in patients with hepatocellular carcinoma (HCC) and
with different 18F-FDG uptake. (A) Protein was extracted from frozen HCC
samples obtained after transsphenoidal surgery. Western blotting was
performed using antibodies against SIRT3 and actin. The images shown
here are cropped and the full-length blots/gels are presented in Add-
itional file 2: Fig. S11. (B) Band quantification was carried out using Ima-
geJ. Statistical analyses were performed using GraphPad Prism. Results
are expressed as mean ± SE. Comparisons between groups were made
using the Mann-Whitney test. *P < 0.05. Supplementary Data 3. TCGA
data analysis. The indicated mRNA level of the Cancer Genome Atlas
(TCGA) Liver Hepatocellular Carcinoma data was obtained from OncoLnc
(www.oncolnc.org) TCGA data portal. Supplementary Data 4. SIRT3 ex-
pression in SIRT3 knockdown and control stable clones. The ratios of the
band intensities were normalized by actin and are reported below the re-
spective panels. The images shown here are cropped and the full-length
blots/gels are presented in Additional file 2: Fig. S12. Supplementary
Data 5. Quantification of immunostaining. We quantified the positive
area of SIRT3 (A) and membranous GLUT1 (C) from indicated xenograft
model in Fig. 2c. (B) We counted the Ki67 positive cells in tumor region
of Fig. 2c. (C) We quantified the positive cells of pRb from indicated
xenograft model in Fig. 4a. (D) Correlation of SIRT3 and pRb was per-
formed in patients with HCC. Statistical analyses were performed using
GraphPad Prism. Results are expressed as mean ± SE (range). Comparisons
between groups were made using the Mann-Whitney test. *, P < 0.05;**,
P < 0.01. Supplementary Data 6. Gene set enrichment analysis (GSEA).
Supplementary Data 7. The effect of combined treatment of sorafenib
and PD033291 on spheroids from HepG2 cells. (A) HepG2 cells were
plated in low-affinity 96-well plates. After the formation of spheroids,
HepG2 cells were treated with vehicle, 10 μM sorafenib, or PD033291 for
the indicated incubation time. (B) Spheroid size was measured using
Image J software after microscopy-based imaging based on six individual
spheroids in each condition. Data are shown as the mean of three inde-
pendent experiments ± SD. Data were analyzed using an unpaired t-test.
*P < 0.05, **P < 0.01. (C) In parallel, western blotting was performed to de-
tect SIRT3 and actin. The images shown here are cropped and the full-
length blots/gels are presented in Additional file 2: Fig. S13.
Supplementary Data 8. Synergistic antitumoral effects of sorafenib and
PD0332991 (A) The cell cycle analysis after treatment with the combin-
ation of sorafenib and PD0332991 in HepG2 and Huh7 cells. (B) HepG2
and Huh7 were plated on coverslips in 24-well plates. The next day, the
cells were incubated with indicated compound. After 24 h, cells were
fixed and processed for immunofluorescent staining with Ki67 protein
and counterstained with DAPI. (C) In parallel, we counted Ki67 positive
cells. (D) Analysis of apoptosis by Annexin V-APC/propidium iodide (PI)
double staining of HepG2 and Huh7 cells. Two-color flow cytometry dot
plots show the percentages of living cells as negative for both annexin V
and PI; early-stage apoptotic cells as the populations testing Annexin V
positive and PI negative, and late-stage apoptotic/necrotic cells as
double-positive cells. Supplementary Data 9. Quantification of western
blotting of Figures.
Additional file 2 Figure S1. Full-length original blots of Fig. 2b. Figure
S2. Full-length original blots of Fig. 2d. Figure S3. Full-length original
blots of Fig. 3a. Figure S4. Full-length original blots of Fig. 3b. Figure
S5. Full-length original blots of Fig. 5a. Figure S6. Full-length original
blots of Fig. 5b (HepG2). Figure S7. Full-length original blots of
Fig. 5c(Huh7). Figure S8. Full-length original blots of Fig. 5d (SK-Hep1).
Figure S9. Full-length original blots of Fig. 6b. Figure S10. Full-length
original blots of Fig. 6d. Figure S11. Full-length original blots of Support-
ing data 2. Figure S12. Full-length original blots of Supporting data 4.
Figure S13. Full-length original blots of Supporting data 7.
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